SB1317
| CAS No. | 1204918-72-8 | Cat. No. | BCP42651 |
| Name | SB1317 | ||
| Synonyms | Ex45; Ex-45; EX 45; TG02; TG 02; TG02; SB1317; SB 1317; Zotiraciclib; | ||
| Formula | C23H24N4O | M. Wt | 372.46 |
| Description | SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. SB1317 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, SB1317 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. SB1317 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). SB1317 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias. | ||
| Related Products | 937270-47-8（SB-1317） | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase Cell Cycle/DNA Damage Jak/Stat Pathway Wnt/Stem Cell Epigenetics | ||
| Targets | FLT3 JAK CDK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.